SOUTH SAN FRANCISCO, Calif., May 24, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that the Company will present at three upcoming investor conferences in June:
Live webcasts of the presentations at the Jefferies and Goldman Sachs healthcare conferences will be available by visiting the Investors section of the Atara Bio website at www.atarabio.com. Archived replays of the webcasts will be available on the Company's website for 14 days following each presentation.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. is a biotechnology company developing T-cell immunotherapies for patients with severe and life-threatening diseases who have been underserved by scientific innovation, with a focus on cancer and autoimmune and infectious diseases. Atara's "Off-the-Shelf" allogeneic T-cell immunotherapy platform harnesses the power of the immune system to recognize and attack cancer cells and cells infected with certain viruses. Atara's most advanced product candidate, ATA129, for cancer patients with rituximab refractory Epstein-Barr virus (EBV) associated Post-Transplant Lymphoproliferative Disease (EBV-PTLD) and other EBV positive solid tumors is expected to enter Phase 3 clinical studies in 2017. The company's clinical stage pipeline also includes cytotoxic T-cells (CTL) targeting Wilms Tumor 1 (WT1), or ATA520, and Cytomegalovirus (CMV), or ATA230. Atara's next generation T-cell immunotherapy for autoimmune disease is an EBV-specific CTL product candidate, or ATA188, that selectively targets specific antigens of EBV believed to be important for the potential treatment of multiple sclerosis (MS).
INVESTOR & MEDIA CONTACTS: Investors: John Craighead, Atara Biotherapeutics 650-491-5806 firstname.lastname@example.org Steve Klass, Burns McClellan 212-213-0006 x331 email@example.com Media: Justin Jackson, Burns McClellan 212-213-0006 x327 firstname.lastname@example.org